Non Hodgkin Lymphoma Clinical Trial
Study to Evaluate CCS1477 in Haematological Malignancies
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
This includes patients with Peripheral T-cell lymphoma.
Provision of consent
ECOG performance status 0-2
Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML)
Must have previously received standard therapy
Adequate organ function
Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose
Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment
Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment
Patients should discontinue statins prior to starting study treatment
CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
Any unresolved reversible toxicities from prior therapy >CTCAE grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy)
Any evidence of severe or uncontrolled systemic diseases
Any known uncontrolled inter-current illness
QTcF prolongation (> 480 msec)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 11 Locations for this study
Phoenix Arizona, 85054, United States
Bordeaux , 33000, France
Villejuif , 94805, France
Barcelona , 08035, Spain
Madrid , 28050, Spain
Stockholm , 171 7, Sweden
Sutton Surrey, SM2 5, United Kingdom More Info
Cardiff , , United Kingdom More Info
Edinburgh , EH4 2, United Kingdom More Info
Glasgow , G12 0, United Kingdom More Info
Leicester , , United Kingdom More Info
London , W1T 7, United Kingdom More Info
Manchester , , United Kingdom More Info
Oxford , , United Kingdom More Info
Southampton , SO16 , United Kingdom More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.